Trial reportPloS one2017
Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial.
Trial report in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Comparison of Ciprofol-Nalbuphine and Propofol-Nalbuphine Sedation During Painless Gastrointestinal Endoscopy: A Randomized Controlled Trial.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- Determining ED50 of Nalbuphine for Intraoperative Analgesia in Elderly Patients Undergoing Percutaneous Kyphoplasty: A Prospective, Double-Blind, Single-Center, Dose-Finding Study.Journal of pain research · 2026Trial
- Efficacy and safety of nalbuphine vs. pethidine in oocyte retrieval: a non-inferiority, double-blinded, randomized controlled trial.Frontiers in reproductive health · 2026Trial
- Comparative efficacy of modified nasopharyngeal airway and nasal cannula for oxygenation in deeply sedated patients undergoing endoscopic retrograde cholangiopancreatography: a randomized controlled trial.BMC anesthesiology · 2025Trial
- Comparative study between nalbuphine and dexmedetomidine for conscious sedation in patients undergoing colonoscopy: randomized comparative trial.BMC anesthesiology · 2025Trial
- Comparison of intravenous nalbuphine and sufentanil on the median effective effect-site concentration of propofol to attenuate the response to cervical dilation during hysteroscopy: a double-blind, dose-response study.BMC anesthesiology · 2025Trial
- Trial
- Adverse Effects of Alfentanil versus Nalbuphine in Decompensated Cirrhotic Patients Undergoing Painless Gastroscopy: A Double-Blind, Randomized Controlled Trial.Drug design, development and therapy · 2025Trial
- Nalbuphine in Pediatric Emergence Agitation Following Cochlear Implantation: A Randomized Trial.Drug design, development and therapy · 2024Trial
- Comparison of propofol-nalbuphine and propofol-fentanyl sedation for patients undergoing endoscopic retrograde cholangiopancreatography: a double-blind, randomized controlled trial.BMC anesthesiology · 2022Trial
- Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy.Medical science monitor : international medical journal of experimental and clinical research · 2021Trial
- Effectiveness of analgesia with hydromorphone hydrochloride for postoperative pain following surgical repair of structural congenital malformations in children: a randomized controlled trial.BMC anesthesiology · 2021Trial
- Combination of propofol and nasal sufentanil or intravenous midazolam for colonoscopy: a comparative study.Anaesthesiology intensive therapy · 2021Trial
- Feasibility of a transmucosal sublingual fentanyl tablet as a procedural pain treatment in colonoscopy patients: a prospective placebo-controlled randomized study.Scientific reports · 2020Trial
- Doxapram alleviates low SpOBMC anesthesiology · 2019Trial
- Effects of patient-controlled analgesia with hydromorphone or sufentanil on postoperative pulmonary complications in patients undergoing thoracic surgery: a quasi-experimental study.BMC anesthesiology · 2018Trial
- Opioid analgesics for sedation-based gastrointestinal endoscopy.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Article
- Efficacy and safety comparison of esketamine-propofol with nalbuphine-propofol for upper gastrointestinal endoscopy in children: a multi-center randomized controlled trial.Frontiers in pediatrics · 2023Article
- Pain management of nalbuphine and sufentanil in patients admitted intensive care unit of different ages.BMC emergency medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesNalbuphine is as effective as morphine as a perioperative analgesic but has not been compared directly with sufentanil in clinical trials. The aims of this study were to compare the efficacy and safety of nalbuphine with that of sufentanil in patients undergoing colonoscopy and to determine the optimal doses of nalbuphine in this indication.
methodsTwo hundred and forty consecutive eligible patients aged 18-65 years with an American Society of Anesthesiologists classification of I-II and scheduled for colonoscopy were randomly allocated to receive sufentanil 0.1 μg/kg (group S), nalbuphine 0.1 mg/kg (group N1), nalbuphine 0.15 mg/kg (group N2), or nalbuphine 0.2 mg/kg (group N3). Baseline vital signs were recorded before the procedure. The four groups were monitored for propofol sedation using the bispectral index, and pain relief was assessed using the Visual Analog Scale and the modified Behavioral Pain Scale for non-intubated patients. The incidences of respiratory depression during endoscopy, nausea, vomiting, drowsiness, and abdominal distention were recorded in the post anesthesia care unit and in the first and second 24-hour periods after colonoscopy.
resultsThere was no significant difference in analgesia between the sufentanil group and the nalbuphine groups (p>0.05). Respiratory depression was significantly more common in group S than in groups N1 and N2 (p<0.05). The incidence of nausea was significantly higher in the nalbuphine groups than in the sufentanil group in the first 24 hours after colonoscopy (p<0.05).
conclusionsNalbuphine can be considered as a reasonable alternative to sufentanil in patients undergoing colonoscopy. Doses in the range of 0.1-0.2 mg/kg are recommended. The decreased risks of respiratory depression and apnea make nalbuphine suitable for patients with respiratory problems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.